Designed to accompany MORSE’s Canadian Reimbursement and Forecasting Timelines (CRaFT) Report, the Health Canada Priority Review & Project Orbis Sub-Report offers credible, relevant insights to support a company’s reimbursement forecasting needs.

WHY DO YOU NEED THIS SUB-REPORT?

This report is essential for understanding the review process, timelines, and funding for drugs under Health Canada Priority Review and Project Orbis, as well as forecasting market access. It provides valuable insights for strategic planning, regulatory navigation, and financial management for stakeholders in the pharmaceutical industry.

WHAT DOES THIS SUB-REPORT INCLUDE?

This sub-report includes 35+ pages of insights on Health Canada Priority Review (oncology and non-oncology) and Project Orbis (oncology) drugs reviewed by CADTH from 2018-2022 related to:

  • CADTH review volume & timeline
  • CADTH & INESSS alignment in recommendations
  • pCPA volume for initiated, completed, closed, and not-negotiated files
  • pCPA under-consideration and under-negotiation timeline
  • Funding volume & timeline for each jurisdiction
  • Timeline Comparison: HC Priority Review (oncology and non-oncology) & Project Orbis (oncology) drugs
  • Market access timeline forecasting (from HTA submission to first funding)

For further information on the content and pricing of CRaFT and the Health Canada Priority Review & Project Orbis Sub-Report, please complete your contact information on our main CRaFT Report page.

← Back to Main CRaFT Report
CRaFT - Health Canada Priority Review & Project Orbis Sub-Report, June 2021 Update